Danaher Co. (NYSE:DHR) Shares Purchased by Copperwynd Financial LLC

Copperwynd Financial LLC raised its position in Danaher Co. (NYSE:DHR) by 7.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,289 shares of the conglomerate’s stock after purchasing an additional 221 shares during the quarter. Copperwynd Financial LLC’s holdings in Danaher were worth $911,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in DHR. Vanguard Group Inc. lifted its holdings in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Swedbank AB acquired a new stake in shares of Danaher during the 1st quarter worth about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after buying an additional 2,096,038 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on DHR. Evercore ISI reduced their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Barclays upped their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last 90 days. 11.10% of the stock is owned by insiders.

Danaher Trading Down 0.4 %

NYSE DHR opened at $275.44 on Friday. The firm’s fifty day moving average price is $270.23 and its 200 day moving average price is $257.87. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $204.01 billion, a price-to-earnings ratio of 46.68, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 EPS. On average, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.